Treatment of CFS and Fibromyalgia With HRG 80 Red Ginseng

NCT ID: NCT04599348

Last Updated: 2020-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-14

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Will a unique form of ginseng be clinically helpful in those with chronic fatigue syndrome and fibromyalgia?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ginseng has been shown in earlier studies to help fatigue in a number of conditions. But because of overharvesting, most ginseng is no longer have optimal levels of the active ginsenosides. A new technique has been developed to restore the level of active ginseng components those found in the wild ginseng used in earlier studies. This is available in a form called HRG 80 Red Ginseng.

The study is an open pilot study to explore whether this treatment would be helpful for improving clinical function and symptomatology in chronic fatigue syndrome and fibromyalgia. Current clinical experience is suggesting that it may be.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia CFS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Open label study
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Ginseng treatment

People with CFS or Fibromyalgia will receive HRG 80 Red GInseng

Group Type EXPERIMENTAL

HRG 80 Red Ginseng

Intervention Type DIETARY_SUPPLEMENT

A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HRG 80 Red Ginseng

A unique form of ginseng with the high level of active ginseng components similar to those found in the wild ginseng used in earlier studies.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. be diagnosed with CFS and/or fibromyalgia
2. live in the United States 3 - be over 18 years of age

Exclusion Criteria

* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Practitioners Alliance Network

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jacob Teitelbaum

Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacob Teitelbaum

Role: PRINCIPAL_INVESTIGATOR

FFTF LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kona Research Center

Kailua, Hawaii, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacob Teitelbaum, MD

Role: CONTACT

4105627409

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacob Teitelbaum

Role: primary

410-562-7409

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PAN-HRG80-2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.